CAR T therapy is a booming sector, with most therapies under investigational phase. Despite its initial success, this therapy faces major manufacturing challenges that compromise its efficacy and accessibility to patients. immUni promises to revolutionize this field, by introducing a medical device that improves the production of these living-drugs. Our technology outperforms top marketed-competitors by achieving a faster and cost-effective process, as well as an end-product with better cell-quality and improved efficacy. After a first strategic introduction to R&D sector (potential licensing option), our product will mature into a clinical solution, serving scaled-up production centers (hospital/industry) and further diversifying into alternative therapeutic segments (rare diseases).
